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1108Objective: Increased myocardial glucose-6-phosphate dehydrogenase (G6PD) activity occurs in heart failure.
This study compared G6PD activity in 2 protocols of right ventricle (RV) systolic overload in young goats.
Methods: Twenty-seven goats were separated into 3 groups: sham (no overload), continuous (continuous sys-
tolic overload), and intermittent (four 12-hour periods of systolic overload paired with a 12-hour resting period).
During a 96-hour protocol, systolic overload was adjusted to achieve a 0.7 RV/aortic pressure ratio. Echocardio-
graphic and hemodynamic evaluations were performed before and after systolic overload every day postopera-
tively. After the study period, the animals were humanely killed for morphologic and G6PD tissue activity
assessment.
Results: A 92.1% and 46.5% increase occurred in RV and septal mass, respectively, in the intermittent group
compared with the sham group; continuous systolic overload resulted in a 37.2% increase in septal mass. A
worsening RV myocardial performance index occurred in the continuous group at 72 hours and 96 hours, com-
pared with the sham (P<.039) and intermittent groups at the end of the protocol (P<.001). Compared with the
sham group, RV G6PD activity was elevated 130.1% in the continuous group (P ¼ .012) and 39.8% in the in-
termittent group (P ¼ .764).
Conclusions: Continuous systolic overload for ventricle retraining causes RV dysfunction and upregulation of
myocardial G6PD activity, which can elevate levels of free radicals by NADPH oxidase, an important mecha-
nism in the pathophysiology of heart failure. Intermittent systolic overload promotes a more efficient RV hyper-
trophy, with better preservation of myocardial performance and and less exposure to hypertrophic triggers.
(J Thorac Cardiovasc Surg 2011;142:1108-13)Supplemental material is available online.
Traditional pulmonary artery banding (PAB) aimed at ven-
tricular retraining causes an abrupt and fixed systolic over-
load. Although clinical studies have proved that PAB
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The Journal of Thoracic and Cardiovascular Surwith inotropic support is generally required. Most impor-
tant, previous studies have demonstrated myocardial edema
and necrosis in hearts that experience abrupt systolic over-
load, followed by late ventricular failure.1
However, it is essential to understand the molecular
mechanisms involved in PAB-induced myocardial hyper-
trophy to establish training protocols that lead to a desirable
‘‘physiologic hypertrophy’’ versus a deleterious ‘‘patho-
logic hypertrophy.’’ Because a known shift occurs in energy
substrate use in favor of glucose in pathologic conditions,
energy metabolism might be altered in PAB ventricular re-
training protocols.2 In addition, recent experimental studies
have linked an unbalanced oxidative and reductive process
to a variety of diseases, such as atherosclerosis and heart
failure.3
Glucose 6-phosphate dehydrogenase (G6PD), the rate-
limiting enzyme that commits glucose to the pentose phos-
phate pathway, is mainly responsible for the generation of
nicotinamide adenine dinucleotide phosphate (NADPH)
and ribose 5-phosphate, an essential precursor of the de
novo synthesis of RNA and DNA. G6PD-derived NADPH,
a cofactor for glutathione and thioredoxin reductase, pre-
serves reducing potentials and protects the cell fromgery c November 2011
Abbreviations and Acronyms
G6P ¼ glucose-6-phosphate
G6PD ¼ glucose 6-phosphate dehydrogenase
LV ¼ left ventricle
NADPþ ¼ oxidized nicotinamide adenine
dinucleotide phosphate
NADPH ¼ nicotinamide adenine dinucleotide
phosphate
PA ¼ pulmonary artery
PAB ¼ pulmonary artery banding
RV ¼ right ventricle
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Doxidative stress in normal conditions.4 In human diseases,
G6PD can be either activated or inhibited; however, evi-
dence has emerged that the overexpression and activation
of G6PD enhances NADPH oxidase–derived superoxide
generation and increases oxidative stress in diseases like di-
abetes, heart failure, and hypertension.5
In regard to rapid ventricular training, it would be of great
interest to study myocardial energy metabolism in response
to different cardiac hypertrophy models and its relationship
to heart function.6 The main objective of this study was to
compare the G6PD activity in 2 right ventricle (RV) training
protocols through an adjustable PAB system.METHODS
Twenty-seven young goats, aged between 30 and 60 days and of com-
parable weight (P ¼ .38), were split into 3 groups: sham (n ¼ 7; weight,
11.93  2.67 kg), continuous (n ¼ 9; weight, 10.74  2.62 kg), and inter-
mittent (n ¼ 11; weight, 10.25  2.20 kg). All animals received humane
care in compliance with the guidelines established by the Brazilian regula-
tions for animal experimentation. The protocol was reviewed and approved
by the Ethics Committee for Research Protocols at the University of S~ao
Paulo Medical School.
Surgical Procedure
All operations were performed with the goats under general anesthesia
(pentobarbital sodium 5mg/kg intravenously and ketamine 20 mg/kg intra-
muscularly) and through a left lateral thoracotomy. The lung was retracted
laterally to allow exposure of the right ventricular outflow tract, pulmonary
trunk, and descending aorta. A 17-gauge heparinized catheter was inserted
into each of these structures, and its corresponding pressures were mea-
sured at specific time intervals during the entire study. The adjustable
PAB system (SILIMED; Silicone e Instrumental Medico-Cirurgico e Hos-
pitalar Ltda, Rio de Janeiro, Brazil) was implanted just beyond the pulmo-
nary valve and sutured at the adventitia of the pulmonary trunk, as
previously described (Figure E1).7 Antibiotics (cefazolin 500 mg and gen-
tamicin 40 mg) were administered daily during the study, as were digoxin
(0.04 mg/kg) and subcutaneous heparin (5000 U).
Training Protocol
RV systolic overload was initiated 72 hours postoperatively. Baseline
hemodynamic data (RV, pulmonary artery [PA], and aortic pressures)
were collected in a conscious, immobilized animal with the adjustable
banding system deflated. Blood pressure measurements were obtainedThe Journal of Thoracic and Carthrough computer software (ACQknowledge 3.01; Biopac Systems, Inc,
Goleta, Calif). Then, the banding system was adjusted to achieve an RV/
aortic pressure ratio of 0.7, limited by a 10% drop in systolic blood pres-
sure. Adjustments were made just once, every morning throughout the pro-
tocol, by percutaneous injection of saline solution with a 3-mL syringe,
under sterile conditions. That rule was violated in case of the latter occur-
ring or if there were agitation, dyspnea, arrhythmia, or a combination of
these. The banding system was then deflated up to a tolerable point.
Continuous Group Protocol
The animals remained with continuous systolic overload for 96 hours,
with daily assessment to keep the RV/aortic pressure ratio at 0.7. Hemody-
namic data were collected once a day (mornings) during PAB
readjustments.
Intermittent Group Protocol
The animals underwent 4 daytime periods of RV 12-hour systolic over-
load, alternating with a 12-hour nighttime resting period. Hemodynamic
datawere collected twice a day (every 12 hours) during PAB readjustments.
Sham Group Protocol
The PAB systemwasmaintained deflated during the entire protocol. He-
modynamic data were collected daily (mornings).
Echocardiography
A single experienced observer conducted the echocardiographic exam-
ination with the animals under light sedation (ketamine 15 mg intramuscu-
larly) approximately 120 hours before the beginning of the protocol and
daily thereafter until the end of the protocol. Image acquisition was ob-
tained through 7.5-MHz and 2.5-MHzmultifrequency transducers (Acuson
Cypress Echocardiology System, Siemens, Erlagen, Germany). The fol-
lowing echocardiographic parameters were studied: left ventricle (LV),
RV, and septal wall thicknesses, RVend-diastolic volume, and myocardial
performance index.
Morphology
Animals were humanely killed after 96 hours of the study protocol. Car-
diac samples were drawn from the RV, LV, and ventricular septum just be-
fore cardiac arrest. These samples were immediately frozen at 80C
(Forma Scientific Inc, Marietta, Ohio) to be subsequently analyzed for
G6PD activity. The pericardial fat, both atria, and semilunar valves were
dissected from the heart; RV, LV, and ventricular septum were separated
by the Fulton technique, individually weighed (METTLER AE-200; Met-
tler-Toledo AG, Greifensee, Switzerland), and indexed to each animal’s
body weight.8
Water content was obtained individually in each cardiac chamber by
subtracting the collected sample weight at autopsy from the weight of
the dehydrated chamber (70 hours at 60C). Values were obtained as a per-
centage of weight change.
G6PD Activity
Tissue samples were homogenized in extraction buffer (proportion 1:5
weight/volume). The material was stored in ice and homogenized for 30
seconds using Polytron (PT 3100; Kinematica AG, Littau-Lucerne, Swit-
zerland) at maximum speed and centrifuging (15 kg, 15 minutes, 4C) to
separate from cell remnants. Enzymatic activity was analyzed using the su-
pernatant of the last centrifugation. Proteins were quantified with the pro-
tein assay kit BCA (PIERCE Biotechnology, Rockford, Ill). Results are
expressed as nmol min1 mg1 of protein. The extraction buffer for
G6PD contained Tris-HCl (50 mmol/L) and ethylenediaminetetraacetic
acid (1 mmol/L), with a pH of 8. The assay buffer (270 mL/sample) was
Tris-HCl (8.6 mmol/L), MgCl2 (6.9 mmol/L), (oxidized nicotinamidediovascular Surgery c Volume 142, Number 5 1109
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Dadenine dinucleotide phosphate (NADPþ; 0.4 mmol/L), and Triton X-100
0.05% (volume/volume), with a pH of 7.6. The reaction was initiated by
adding 15 mL of glucose-6-phosphate (G6P; 1.2 mmol/L) to the enzymatic
extract (15 mL of sample) for 10 minutes at 25C. The absorbance was
monitored at 340 nm, the extinction coefficient being 6.22 for that partic-
ular wavelength. The biochemical reaction is based on the glucose phos-
phorylation into G6P, and posterior formation of 6-phosphogluconate by
the action of G6PD. The G6PD activity was indirectly determined by the
total production of NADPH through the pentose phosphate pathway.9 RV
and ventricular septum values were indexed to each animal’s LV value.
Statistical Analysis
Values are expressed as means and standard deviation. Comparison of
variables was performed with 2-way analysis of variance, except for
body weight, G6PD activity, wall masses, and water content, which were
performed with 1-way analysis of variance. Both analyses were followed
by the Bonferroni post hoc test. The level of significance used was 5%. Sta-
tistical analysis was performed using GraphPad Prism version 4 software
(GraphPad Prism, La Jolla, Calif) and SigmaStat 3.11.0 for Windows (Sy-
stat Software, Inc, Chicago, Ill).FIGURE 1. A, RV-PA gradient (mm Hg) temporal pattern of sham, con-
tinuous, and intermittent groups. B, According to variations in RV-PA gra-
dients in relation to time, the area under the curve (mm Hg h) was
calculated to determine the systolic overload imposed on each group. RV,
Right ventricle; PA, pulmonary artery. *P< .001 compared with that of
the sham group. #P<.001 compared with the intermittent group.RESULTS
Hemodynamic Variables
Systolic RV-PA gradient increased in both study groups
(P<.001) and in every time period (P<.001). There was
no significant difference of banding gradients between the
2 study groups on each day of the protocol, being both sub-
mitted to the same magnitude of systolic overload stimulus
(Table E1). Likewise, both study groups showed an in-
creased RV-aorta systolic pressure ratio over time
(Figure E2) compared with its respective baseline and
with that in the sham group at the same time (P<.05). There
were peak systolic gradients in the intermittent group, alter-
nating with 12-hour rest periods when they were similar to
those in the sham group (Figure 1, A). The small RV-PA gra-
dient (3.83 1.33 mmHg to 5.50 1.38 mmHg) observed
in the sham group is considered physiologic. To quantify the
exposure to systolic overload, we determined the area under
the RV-PA gradient curve (Figure 1, B). The continuous
group was the group most exposed to systolic overload
(P<.05).TABLE 1. RV wall thickness of the 3 groups measured by
echocardiography in each time period of the protocol
Time (h)
RV wall thickness (mm)
Sham (n ¼ 7) Continuous (n ¼ 9) Intermittent (n ¼ 11)
Preop 3.24  0.14 3.28  0.35 2.87  0.58
0 3.30  0.15 3.31  0.33 2.98  0.51
24 3.36  0.11 3.37  0.33 3.02  0.59
48 3.39  0.09 3.63  0.68 3.91  0.81*
72 3.37  0.14 4.40  0.64*,y 4.85  0.66*,y
96 3.36  0.08 4.54  0.51*,y 5.85  1.32*,y,z
Values (mm) ¼ means  standard deviation. *P<.001 compared with its respective
baseline value. yP<.001 compared with that in the sham group at the same time.
zP<.001 compared with that in the continuous group at the same time.Echocardiographic Variables
RV wall thickness was thinner than septal and LV thick-
nesses in all animals preoperatively (group factor, P¼ .663;
heart wall factor, P<.001). There was a marked increase in
RV wall thickness after 48 hours in the intermittent group
and after 72 hours in the continuous group compared with
the baseline values (Table 1). The intermittent group devel-
oped a thicker RV wall (5.85 mm 1.32 mm) than the con-
tinuous group did (4.54 mm  0.51 mm) at 96 hours
(P< .001). At the end of the training protocol, RV wall
thickness increased 103.8% in the intermittent group and
only 38.4% in the continuous group. No significant differ-
ences occurred in septal and LV wall thicknesses among
groups (P ¼ .491) and across time (P ¼ .865). The graph1110 The Journal of Thoracic and Cardiovascular Surwith the percentage of changes in RV wall thickness is
available online (Figure E3).
Regarding RV end-diastolic volume, there was a signifi-
cant difference among groups (P< .001) and throughout
the protocol (P ¼ .024). RV volume was significantly di-
lated in the continuous group at 24 hours and thereafter,
compared with that in the intermittent and sham groupsgery c November 2011
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FIGURE 2. RV myocardial performance index during the 96-hour proto-
col in sham, continuous, and intermittent groups. RV, Right ventricle.
¤P < .04 compared with that in the sham group at the same time.
#P<.001 compared with that in the intermittent group at the same time.
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D(P<.001). The graph with the percentage of changes in RV
end-diastolic volume is available online (Figure E4). Wors-
ening of RVmyocardial performance index was observed in
the continuous group at 72 hours and 96 hours of the proto-
col, compared with that in the sham group (P<.039) and the
intermittent group (P< .001) at the end of the protocol
(Figure 2).Morphologic Variables
As demonstrated in Figure 3, the intermittent group had
a 92.1% increase in RV mass (1.46  0.53 g/kg) and
a 46.5% increase in ventricular septal mass (1.26  0.29
g/kg) compared with the RV (0.76 0.12 g/kg) and ventric-
ular septal (0.86  0.10 g/kg) masses in the sham group
(P<.05). On the other hand, the continuous group had an
increase only in the ventricular septal mass (1.18  0.14
g/kg; P<.05). LV mass was not altered by RV training pro-
tocols (P ¼ .217). Regarding water content, both RV
(81.59%  1.07%) and ventricular septum (79.69% 
0.62%) in the continuous group and both RV (81.84% 
1.11%) and ventricular septum (79.45%  0.62%) in the
intermittent group had a mild, however significant, increaseRV Mass Ventricular S
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FIGURE 3. RV, ventricular septum, and LV weights in the 3 groups, indexed t
tricle; LV, left ventricle. *P<.05 compared with that in the sham group.
The Journal of Thoracic and Carcompared with that in the sham group (RV, 78.84% 
2.41%; ventricular septum, 77.11%  2.08%; P< .01).
No significant changes were observed in LV water content
in the 3 groups.G6PD Activity
G6PDactivity ratio ofRV to LVwas significantly elevated
by 130.1% in the continuous group (P¼ .012), whereas the
intermittent group showed a nonsignificant smaller increase
of 39.8% in the G6PD activity ratio of RV to LV (P¼ .764)
compared with that in the sham group (Figure 4). There was
no significant difference in the ventricular septum to LV
G6PD activity ratio among groups (P ¼ .198).DISCUSSION
The present experimental study aimed to compare PAB-
induced RV hypertrophy in continuous versus intermittent
systolic overload in young goats, with the emphasis on
G6PD activity analysis. Both study groups were capable
of promoting different degrees of myocardial hypertrophy
compared with the sham group. However, the intermittent
group had greater RV and ventricular septal masses than
the continuous group had, despite less exposure to systolic
overload. The mild increase in RV and ventricular septum
water content in both trained groups would not by itself jus-
tify the previous findings, suggesting that it was probably
related to the enhanced protein synthesis and cell prolifera-
tion, as previously documented by Abduch and col-
leagues.10 The continuous group had a series of
deleterious effects at the end of the protocol. Persistent
RV dilation was followed by impaired RV function and in-
creased G6PD activity, G6PD being the rate-limiting en-
zyme in the oxidative branch of the pentose phosphate
pathway. Because the pentose phosphate pathway is one
of the major sources of NADPH in cardiac myocytes, this
is an important finding, and it may indicate an unbalanced
redox, with the occurrence of oxidative stress and genera-
tion of reactive oxygen species related to NADPH oxi-
dase.11 In pathologic conditions, the excessive production
of NADPH via G6PD overexpression is a result of multipleeptum Mass 
**
Sham      Continuous Intermittentinuous Intermittent
LV Mass 
o body weight. Values (g/kg) ¼ mean  standard deviation. RV, Right ven-
diovascular Surgery c Volume 142, Number 5 1111
FIGURE 4. RV/LV ratio of G6PD activity in the sham, continuous, and
intermittent groups. Values ¼ mean  standard deviation. Sham: n ¼ 5;
continuous: n¼ 5; intermittent: n¼ 10. RV, Right ventricle; LV, left ventri-
cle; G6PD, glucose 6-phosphate dehydrogenase. *P<.05 compared with
that in the sham and intermittent groups.
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sis factor alpha. The final consequence of this cascade of
events would be the cardiomyopathy related to protein ag-
gregation owing to reductive stress.12,13
It has been demonstrated that either G6PD activation or
inhibition is associated with diseases. However, growing
evidence has emerged that G6PD overexpression correlates
with oxidative and reductive stress, and new investigational
drugs are currently under development to suppress its ac-
tion.14 For instance, diabetic patients had upregulation of
G6PD with high NADPH levels, and that was linked to in-
hibition of nitric oxide synthesis and endothelial dysfunc-
tion.15 Although the mechanisms underlying the increased
production of reactive oxygen species in the heart are not
completely understood, it has been proposed that the high
rate of glucose oxidation increases mitochondrial mem-
brane potential, which enhances production of superoxide
anion.16,17 The latter would be a modulator in diabetic
vasculopathy and precede the development of diabetic
cardiomyopathy.18,19
Furthermore, in pacing-induced heart failure, an estab-
lished model of dilated cardiomyopathy in dogs, it has
been demonstrated that a 10-fold overexpression of G6PD
occurs compared with that in controls.20 Recent studies
demonstrated that G6PD upregulation in mice adipocytes
has been implicated as one of the causes of altered hormonal
release observed in obesity and insulin resistance.21
Although the present work has not evaluated the genera-
tion of reactive oxygen species related to NADPH oxidase,
it is tempting to speculate that, in case of persistent systolic
overload, upregulation and hyperactivity of myocardial
G6PD observed in the continuous group strongly suggest
that the pentose phosphate pathway enhances cytosolic
NADPH availability, thus fueling free radical production
by NADPH oxidase and uncoupled nitric oxide synthase.
Therefore, it may induce superoxide anion myocardial1112 The Journal of Thoracic and Cardiovascular Surinjury, as well as protein aggregation, and subsequently
heart failure. However, other unknown mechanisms of
G6PD in heart failure could not be ruled out. This issue
has been investigated worldwide.
Regarding the training protocol, previous studies have
demonstrated that ventricular training protocols induce
myocardial hypertrophy 96 hours after progressive systolic
overload.22 The search for a physiologic hypertrophy has
been the focus of our laboratory for over 2 decades, and
we postulate that intermittent systolic overload promotes
the desirable effects of myocardial hypertrophy without
its adverse effects.7 RV-PA gradients were more pro-
nounced in the intermittent group after 48 hours of training.
We would argue that the 12-hour resting period allowed the
myocardium to replenish energy substrates and reestablish
subendocardial perfusion owing to a lower ventricular
wall tension. That would probably provide better hemody-
namic performance at periods of systolic overload.23
Study Limitations
First, inferences based on animal findings do not neces-
sarily translate into the same conclusions in humans. Sec-
ond, RV hypertrophy was studied here, as opposed to
human hearts with transposition of the great arteries. How-
ever, experimental models of aortic banding are associated
with prohibited mortality rates.24 It is difficult to make de-
finitive conclusions about a hypertrophic process based on
a single enzyme activity. Nevertheless, it is essential to
correlate these biochemical findings with production of su-
peroxide anions and apoptosis to better understand the role
of oxidative stress in hypertrophy training protocols. Previ-
ous studies have demonstrated that the oxidative branch of
the pentose phosphate pathway, which produces NADPH
and ribulose 5-phosphate, is essentially irreversible, being
controlled primarily by G6PD activity and, hence, the
NADPH/NADP ratio.25 NADPH oxidase preferentially
uses NADPH derived from the pentose phosphate pathway,
and that, in the failing heart, more glucose is oxidized
through the pentose phosphate pathway, with a consequent
increase in electron donors available to fuel O2
generating
enzymes. Maybe that is the way NADPþ is upregulated. Al-
though this is a nonspecific pathway of free radical produc-
tion, we have found a concordance of impaired RV
function of continuous group and increased G6PD. Never-
theless, it would be more objective if we had measured
oxygen-derived free radicals or tissue injury markers re-
lated to their production. Therefore, it is somehow difficult
to assume and interpret a whole metabolic pathway based
on the activity of a single enzyme. Future studies are being
planned in our laboratory for the detection of increased ox-
idized glutathione, oxygen-derived free radicals, and myo-
cardial injury markers that further supports the presence of
a state of oxidative stress in the RV of the continuous
group.gery c November 2011
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DCONCLUSIONS
This study demonstrates that continuous systolic over-
load for ventricle retraining causes hyperactivity in myocar-
dial G6PD, together with RV dilation and dysfunction. That
enzyme hyperactivity may be related to an unbalanced re-
dox determined by a constant and pathologic systolic over-
load. Given that pentose phosphate pathway enhances
cytosolic NADPH availability, this altered energy substrate
metabolism can elevate levels of free radicals by NADPH
oxidase, an important mechanism in the pathophysiology
of heart failure. On the other hand, intermittent systolic
overload has promoted a more efficient RV hypertrophy
than the continuous one, with better preservation of myo-
cardial performance and smaller G6PD activity. Clinical
studies comparing adjustable and traditional pulmonary
trunk banding should be welcomed to translate those find-
ings to the practice of ventricular retraining.
We are grateful to Sachin A. Gupte, MD, PhD, from University
of South Alabama, for his helpful suggestions on the revised
manuscript.
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Dr William J. Brawn (Birmingham, United Kingdom). I have
no disclosures. I have 2 questions.
In the human situation, acutely raising the ventricular ratio to
70% is usually followed by a fall in this ratio, probably with an as-
sociated falling cardiac output. How do you adjust the band, and
how frequently, to maintain that 70% ratio in your animals?
DrAtik.That is a very good point. Thank you for your question.
In our study, we performed the operation, and we have allowed
the heart to recover for 72 hours beforewe initiated training. By the
time we did it, we tightened the band to achieve that ratio. Some-
times we have to loosen it a little bit because there was a drop of
more than 10% in systolic blood pressure or there were arrhyth-
mias or agitation and hypoxia. So we went back to 0.5 or 0.6 ratio
and waited a few minutes and then we tried it again. If it was not
possible, we left the band tightened up to a tolerable point for the
animal. Reassessments were made every 24 hours and in almost all
the animals we had to readjust at that time.
Dr Brawn. Thank you. Final question, have you any insight as
to how long it takes to upregulate the G6PD activity, how acutely it
occurs?
Dr Atik. We do not have an answer for that question. This is
a very good point. Actually, G6PD activity has a 2-fold mecha-
nism. First, it enhances ribose 6-phosphate, which is a precursor
of de novo production of DNA, which is good for hypertrophy.
On the other hand, G6PD may enhance superoxide anion genera-
tion, which is bad for hypertrophy and can induce myocardial in-
jury. Sowe really do not know how long does it take tomodulate its
activity.diovascular Surgery c Volume 142, Number 5 1113
FIGURE E1. Pulmonary trunk adjustable banding device used in the pro-
tocol, manufactured by SILIMED, Silicone e Instrumental Medico-Cirur-
gico e Hospitalar Ltda, Rio de Janeiro, Brazil.
FIGUREE2. RV/aorta systolic pressure ratio of sham, continuous, and in-
termittent groups, throughout the protocol. RV, Right ventricle. *P<.05
compared with its respective baseline and with that in the sham group at
the same time.
FIGUREE3. D% changes of RV wall thickness of sham, continuous, and
intermittent groups throughout the protocol. RV, Right ventricle. *P<.001
compared with the respective baseline value. #P<.001 compared with the
sham group at the same time.þþP< .02 compared with the continuous
group at the same time.
FIGURE E4. D% changes of RVend-diastolic volume of sham, continu-
ous, and intermittent groups throughout the protocol. RV, Right ventricle.
*P<.001 compared with the respective baseline value. #P<.001 compared
with the sham group at the same time.
TABLE E1. RV-PA systolic pressure gradients of the 3 groups in each
time period of the protocol
Time (h)
RV-PA gradient (mm Hg)
P value*Sham Continuous Intermittent
Baseline 5.43  1.99 8.00  3.79 7.73  6.40 1.00
0 5.43  1.99 49.63  16.70 48.00  10.93 1.00
24 5.43  1.27 49.43  14.37 55.73  9.91 .69
48 5.43  1.13 58.88  11.43 63.82  13.69 .97
72 5.50  1.38 60.88  15.72 69.18  9.78 .30
96 3.83  1.33 51.29  21.47 66.20  11.37 .06
Values ¼ mean  standard deviation. RV, Right ventricle; PA, pulmonary artery.
*P value of comparisons for continuous 3 intermittent groups.
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